TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $40.67.

A number of equities research analysts have issued reports on TGTX shares. JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 14th. HC Wainwright increased their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Finally, The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $759,000. Segall Bryant & Hamill LLC purchased a new stake in TG Therapeutics in the 3rd quarter valued at approximately $1,225,000. Barclays PLC grew its holdings in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. Principal Financial Group Inc. increased its position in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of TG Therapeutics in the third quarter worth $2,358,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Down 0.4 %

Shares of NASDAQ TGTX opened at $30.95 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $4.82 billion, a PE ratio of -309.47 and a beta of 2.25. TG Therapeutics has a twelve month low of $12.84 and a twelve month high of $36.84. The stock has a fifty day simple moving average of $29.42 and a 200-day simple moving average of $23.79.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter last year, the company earned $0.73 earnings per share. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. On average, equities analysts forecast that TG Therapeutics will post 0.17 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.